Tucidinostat (Epidaza (in China), not yet branded in other markets)
Other Medications
Description
Tucidinostat (also known as chidamide) is a selective histone deacetylase (HDAC) inhibitor that has shown promise in treating microsatellite stable (MSS) colorectal cancer when combined with immunotherapy and anti-angiogenic agents. This epigenetic modifier is being used in combination regimens specifically for MSS/proficient mismatch repair (pMMR) colorectal cancer patients, a population that typically responds poorly to immunotherapy alone. The drug works to enhance immune response in tumors that are traditionally considered "cold" to immunotherapy.
Mechanism of Action
Tucidinostat selectively inhibits class I and IIb histone deacetylases, particularly HDAC1, HDAC2, HDAC3, and HDAC10. This inhibition leads to increased acetylation of histones and non-histone proteins, resulting in enhanced tumor antigen presentation, increased T-cell infiltration, and improved sensitivity to PD-1/PD-L1 inhibitors in microsatellite stable colorectal cancers.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Epidaza (in China), not yet branded in other markets |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Not submitted to EMA |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.